Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00133705 · ClinicalTrials.gov registry record · Phase 3

Trial of Mifepristone for Fibroids

A Phase 3 study of Leiomyoma, sponsored by University of Rochester.

Completed
Registry status
Phase 3
Development phase
70
Enrollment target
1
Study location

NCT00133705 is a Phase 3 study of Leiomyoma that has completed, run by University of Rochester. The registered enrollment target is 70 participants, below the 97-participant average among 8 other Leiomyoma trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00133705, a Phase 3 study of Leiomyoma, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
Phase 3
Development phase
70 participants
Enrollment target
1
Study location

Study Summary

The purpose of this trial is to determine if low-dose mifepristone benefits women with symptomatic fibroids.

Conditions Studied

Interventions

  • DRUG Mifepristone
  • DRUG Inert Capsule

Study Locations (1)

New York

  • University of Rochester School of Medicine & Dentistry - Rochester

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2003-07
Est. Completion 2010-06
Phase Phase 3

Sponsor

University of Rochester

636 total trials

What the Registry Record Tells You About NCT00133705

The ClinicalTrials.gov registry entry for NCT00133705 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 8 other Leiomyoma trials with a reported enrollment target (28% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Leiomyoma appearing as the primary indexed condition, and to 2 interventions - of which Mifepristone is the first listed.

NCT00133705 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT00133705 about?

NCT00133705 is a clinical study titled "Trial of Mifepristone for Fibroids". The purpose of this trial is to determine if low-dose mifepristone benefits women with symptomatic fibroids.

What is the current status of trial NCT00133705?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 70 participants. The study started on 2003-07. Estimated completion is 2010-06.

What conditions does trial NCT00133705 study?

This clinical trial studies the following conditions: Leiomyoma.

What interventions are being tested in trial NCT00133705?

The interventions under investigation include: Mifepristone (DRUG), Inert Capsule (DRUG).

Who is sponsoring clinical trial NCT00133705?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00133705 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leiomyoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.